1982
Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction
Miliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaMedian ageStage IVPrimary siteHistologic distinctionIntra-abdominal involvementFive-year survivalNational Cancer InstituteMedian survivalBurkitt's typeRetrospective studyHodgkin's lymphomaPatient populationLonger survivalCancer InstituteLymphomaPatientsSurvivalDiseaseMonthsAgePresentationYearsCases
1981
Natural history of malignant lymphomas with divergent histologies at staging evaluation
Fisher R, Jones R, Devita V, Simon R, Garvin A, Berard C, Young R. Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer 1981, 47: 2022-2025. PMID: 7226096, DOI: 10.1002/1097-0142(19810415)47:8<2022::aid-cncr2820470820>3.0.co;2-v.Peer-Reviewed Original ResearchConceptsDifferent histologic diagnosesHistologic diagnosisNatural historyStaging evaluationMalignant lymphomaDiffuse patternNodular patternTissue sitesComplete response rateInitial staging evaluationNational Cancer InstituteMultiple tissue sitesMedian survivalMedical recordsCancer InstituteDivergent histologyPatientsBiopsyResponse ratePlanning treatmentUnique natural historyDiagnosisMonthsLymphomaTreatment
1979
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine
1976
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Canellos G, DeVita V, Gold G, Chabner B, Schein P, Young R. Combination chemotherapy for advanced breast cancer: response and effect on survival. Annals Of Internal Medicine 1976, 84: 389-92. PMID: 1259283, DOI: 10.7326/0003-4819-84-4-389.Peer-Reviewed Original ResearchConceptsMedian survivalBreast cancerFunctional liver impairmentPrevious cytotoxic therapyAdvanced breast cancerMetastatic breast cancerHormonal therapyLiver impairmentMetastatic diseasePartial responseCombination chemotherapyComplete responseNodal metastasisCytotoxic therapyEndocrine ablationPatientsFourteenth daySoft tissueEighth daySurvivalTherapyCancerMonthsDaysResponsive sites
1975
Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids)
Ihde D, Devita V. Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids). Cancer 1975, 36: 1585-1588. PMID: 1192349, DOI: 10.1002/1097-0142(197511)36:5<1585::aid-cncr2820360508>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsCombination chemotherapyFemoral headHigh-dose prednisoneIntermittent combination chemotherapyWeeks of therapyInitiation of therapyLong-term complicationsNecrosis of boneSteroid administrationAdult patientsMalignant lymphomaPatientsChemotherapyLymphomaOsteonecrosisComplicationsTherapyPrednisoneVincristineNecrosisHeadAdministrationWeeksMonthsResults of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvival